{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T21:29:43Z","timestamp":1790026183091,"version":"4.0.1"},"reference-count":94,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2019,3,17]],"date-time":"2019-03-17T00:00:00Z","timestamp":1552780800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Romanian Academy of Medical Sciences and European Regional Development Fund"},{"name":"MySMIS","award":["2\/Axa 1\/31.07.2017\/107124"],"award-info":[{"award-number":["2\/Axa 1\/31.07.2017\/107124"]}]},{"name":"Ministery of Research and Innovation"},{"name":"CNCS-UEFISCDI","award":["PN-III-P4-ID-PCE-2016-0908"],"award-info":[{"award-number":["PN-III-P4-ID-PCE-2016-0908"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,6,1]]},"DOI":"10.1093\/ndt\/gfz040","type":"journal-article","created":{"date-parts":[[2019,2,2]],"date-time":"2019-02-02T20:08:57Z","timestamp":1549138137000},"page":"923-933","source":"Crossref","is-referenced-by-count":26,"title":["Pros and cons of antithrombotic therapy in end-stage kidney disease: a 2019 update"],"prefix":"10.1093","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3424-1588","authenticated-orcid":false,"given":"Alexandru","family":"Burlacu","sequence":"first","affiliation":[{"name":"Department of Interventional Cardiology, Cardiovascular Diseases Institute, \u2018Grigore T. Popa\u2019 University of Medicine, Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simonetta","family":"Genovesi","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, San Gerardo Hospital, University of Milan Bicocca Nephrology Unit, Monza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Ortiz","sequence":"additional","affiliation":[{"name":"IIS-Fundacion Jimenez Diaz UAM, FRIAT and REDINREN, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Combe","sequence":"additional","affiliation":[{"name":"Service de N\u00e9phrologie Transplantation Dialyse Aph\u00e9r\u00e8se, Centre Hospitalier Universitaire de Bordeaux, Unit\u00e9 INSERM 1026, Universit\u00e9 de Bordeaux, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Basile","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Miulli General Hospital, Acquaviva delle Fonti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0124-1012","authenticated-orcid":false,"given":"Daniel","family":"Schneditz","sequence":"additional","affiliation":[{"name":"Otto Loewi Research Center, Medical University of Graz, Graz, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"van der Sande","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Nephrology, University Hospital Maastricht, Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grigore T","family":"Popa","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Regional Institute of Oncology, University of Medicine, Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornel","family":"Morosanu","sequence":"additional","affiliation":[{"name":"Nephrology Clinic, Dialysis and Renal Transplant Center, \u2018C.I. Parhon\u2019 University Hospital, \u2018Grigore T. Popa' University of Medicine, Iasi, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Covic","sequence":"additional","affiliation":[{"name":"the Academy of Romanian Scientists (AOSR)"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,3,16]]},"reference":[{"key":"2019060303554041000_gfz040-B1","doi-asserted-by":"crossref","first-page":"A7","DOI":"10.1053\/j.ajkd.2016.12.004","article-title":"US Renal Data System 2016 Annual Data Report: epidemiology of kidney disease in the United States","volume":"69","author":"Saran","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"2019060303554041000_gfz040-B2","doi-asserted-by":"crossref","first-page":"h246","DOI":"10.1136\/bmj.h246","article-title":"The association between kidney function and major bleeding in older adults with atrial fibrillation starting warfarin treatment: population based observational study","volume":"350","author":"Jun","year":"2015","journal-title":"BMJ"},{"key":"2019060303554041000_gfz040-B3","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s12916-018-1145-0","article-title":"Practical issues in clinical scenarios involving CKD patients requiring antithrombotic therapy in light of the 2017 ESC guideline recommendations","volume":"16","author":"Covic","year":"2018","journal-title":"BMC Med"},{"key":"2019060303554041000_gfz040-B4","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1093\/ndt\/gfx041","article-title":"The quest for equilibrium: exploring the thin red line between bleeding and ischaemic risks in the management of acute coronary syndromes in chronic kidney disease patients","volume":"32","author":"Burlacu","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"2019060303554041000_gfz040-B5","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur Heart J"},{"key":"2019060303554041000_gfz040-B6","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.cjca.2014.08.001","article-title":"2014 focused update of the Canadian Cardiovascular Society guidelines for the management of atrial fibrillation","volume":"30","author":"Verma","year":"2014","journal-title":"Can J Cardiol"},{"key":"2019060303554041000_gfz040-B7","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","article-title":"The 2018 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"39","author":"Steffel","year":"2018","journal-title":"Eur Heart J"},{"key":"2019060303554041000_gfz040-B8","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1093\/eurheartj\/ehy060","article-title":"Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"39","author":"Turakhia","year":"2018","journal-title":"Eur Heart J"},{"key":"2019060303554041000_gfz040-B9","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/europace\/euy174","article-title":"2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and\/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA)","volume":"21","author":"Lip","year":"2019","journal-title":"Europace"},{"key":"2019060303554041000_gfz040-B10","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.cjca.2016.08.018","article-title":"Are existing risk scores for nonvalvular atrial fibrillation useful for prediction or risk adjustment in patients with chronic kidney disease?","volume":"33","author":"McAlister","year":"2017","journal-title":"Can J Cardiol"},{"key":"2019060303554041000_gfz040-B11","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1093\/eurheartj\/ehu139","article-title":"Balancing stroke and bleeding risks in patients with atrial fibrillation and renal failure: the Swedish Atrial Fibrillation Cohort study","volume":"36","author":"Friberg","year":"2015","journal-title":"Eur Heart J"},{"key":"2019060303554041000_gfz040-B12","doi-asserted-by":"crossref","first-page":"492","DOI":"10.7326\/0003-4819-131-7-199910050-00003","article-title":"Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis","volume":"131","author":"Hart","year":"1999","journal-title":"Ann Intern Med"},{"key":"2019060303554041000_gfz040-B13","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.1093\/ndt\/gfs416","article-title":"Systematic review and meta-analysis of incidence, prevalence and outcomes of atrial fibrillation in patients on dialysis","volume":"27","author":"Zimmerman","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"2019060303554041000_gfz040-B14","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1016\/j.jacc.2014.09.051","article-title":"Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study","volume":"64","author":"Bonde","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2019060303554041000_gfz040-B15","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1681\/ASN.2009030319","article-title":"Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation","volume":"20","author":"Chan","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"2019060303554041000_gfz040-B16","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1038\/ki.2009.477","article-title":"Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy","volume":"77","author":"Wizemann","year":"2010","journal-title":"Kidney Int"},{"key":"2019060303554041000_gfz040-B17","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s40620-016-0364-8","article-title":"Effect of oral anticoagulant therapy on mortality in end-stage renal disease patients with atrial fibrillation: a prospective study","volume":"30","author":"Genovesi","year":"2017","journal-title":"J Nephrol"},{"key":"2019060303554041000_gfz040-B18","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.2215\/CJN.02400311","article-title":"Warfarin in atrial fibrillation patients with moderate chronic kidney disease","volume":"6","author":"Hart","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"2019060303554041000_gfz040-B19","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1001\/jama.2014.1334","article-title":"Warfarin, kidney dysfunction, and outcomes following acute myocardial infarction in patients with atrial fibrillation","volume":"311","author":"Carrero","year":"2014","journal-title":"JAMA"},{"key":"2019060303554041000_gfz040-B20","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1105594","article-title":"Stroke and bleeding in atrial fibrillation with chronic kidney disease","volume":"367","author":"Olesen","year":"2012","journal-title":"N Engl J Med"},{"key":"2019060303554041000_gfz040-B21","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1093\/europace\/euv289","article-title":"Ischaemic stroke in patients with atrial fibrillation with chronic kidney disease undergoing peritoneal dialysis","volume":"18","author":"Chan","year":"2016","journal-title":"Europace"},{"key":"2019060303554041000_gfz040-B22","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.hrthm.2017.01.047","article-title":"Warfarin use and the risk of mortality, stroke, and bleeding in hemodialysis patients with atrial fibrillation","volume":"14","author":"Kai","year":"2017","journal-title":"Heart Rhythm"},{"key":"2019060303554041000_gfz040-B23","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1378\/chest.15-1719","article-title":"Stroke, major bleeding, and mortality outcomes in warfarin users with atrial fibrillation and chronic kidney disease: a meta-analysis of observational studies","volume":"149","author":"Dahal","year":"2016","journal-title":"Chest"},{"key":"2019060303554041000_gfz040-B24","doi-asserted-by":"crossref","first-page":"341","DOI":"10.5301\/jn.5000010","article-title":"Prevalence of atrial fibrillation and warfarin use in older patients receiving hemodialysis","volume":"25","author":"Winkelmayer","year":"2012","journal-title":"J Nephrol"},{"key":"2019060303554041000_gfz040-B25","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1053\/j.ajkd.2015.05.019","article-title":"Outcomes after warfarin initiation in a cohort of hemodialysis patients with newly diagnosed atrial fibrillation","volume":"66","author":"Shen","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"2019060303554041000_gfz040-B26","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1093\/ndt\/gfu334","article-title":"Warfarin use, mortality, bleeding and stroke in haemodialysis patients with atrial fibrillation","volume":"30","author":"Genovesi","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"2019060303554041000_gfz040-B27","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nrneph.2018.19","article-title":"Use of oral anticoagulants in patients with atrial fibrillation and renal dysfunction","volume":"14","author":"Potpara","year":"2018","journal-title":"Nat Rev Nephrol"},{"key":"2019060303554041000_gfz040-B28","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1053\/j.ajkd.2007.10.034","article-title":"Atrial fibrillation and morbidity and mortality in a cohort of long-term hemodialysis patients","volume":"51","author":"Genovesi","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"2019060303554041000_gfz040-B29","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/sdi.12338","article-title":"Clopidogrel use in end-stage kidney disease","volume":"28","author":"Tanios","year":"2015","journal-title":"Semin Dial"},{"key":"2019060303554041000_gfz040-B30","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1159\/000448898","article-title":"Patients' characteristics affect the survival benefit of warfarin treatment for hemodialysis patients with atrial fibrillation. a historical cohort study","volume":"44","author":"Brancaccio","year":"2016","journal-title":"Am J Nephrol"},{"key":"2019060303554041000_gfz040-B31","first-page":"234","volume-title":"Nephrology","author":"Tan","year":"2019"},{"key":"2019060303554041000_gfz040-B32","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1053\/j.ajkd.2016.10.018","article-title":"Warfarin initiation, atrial fibrillation, and kidney function: comparative effectiveness and safety of warfarin in older adults with newly diagnosed atrial fibrillation","volume":"69","author":"Jun","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"2019060303554041000_gfz040-B33","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s40620-015-0236-7","article-title":"Atrial fibrillation and low vitamin D levels are associated with severe vascular calcifications in hemodialysis patients","volume":"29","author":"Fusaro","year":"2016","journal-title":"J Nephrol"},{"key":"2019060303554041000_gfz040-B34","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1053\/j.ajkd.2014.11.004","article-title":"Influence of kidney function on risk of supratherapeutic international normalized ratio-related hemorrhage in warfarin users: a prospective cohort study","volume":"65","author":"Limdi","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"2019060303554041000_gfz040-B35","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.004925","article-title":"Time in therapeutic range and outcomes after warfarin initiation in newly diagnosed atrial fibrillation patients with renal dysfunction","volume":"6","author":"Szummer","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"2019060303554041000_gfz040-B36","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/ki.2012.345","article-title":"Chronic kidney disease alters intestinal microbial flora","volume":"83","author":"Vaziri","year":"2013","journal-title":"Kidney Int"},{"key":"2019060303554041000_gfz040-B37","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/hdi.12486","article-title":"The gut-kidney axis in chronic renal failure: a new potential target for therapy","volume":"21","author":"Khoury","year":"2017","journal-title":"Hemodial Int"},{"key":"2019060303554041000_gfz040-B38","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1093\/eurheartj\/ehr226","article-title":"Patients using vitamin K antagonists show increased levels of coronary calcification: an observational study in low-risk atrial fibrillation patients","volume":"32","author":"Weijs","year":"2011","journal-title":"Eur Heart J"},{"key":"2019060303554041000_gfz040-B39","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.1523-1755.2005.00421.x","article-title":"Pathogenesis of vascular calcification in chronic kidney disease","volume":"68","author":"Cozzolino","year":"2005","journal-title":"Kidney Int"},{"key":"2019060303554041000_gfz040-B40","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.2215\/CJN.13921217","article-title":"The effect of increasing dialysate magnesium on serum calcification propensity in subjects with end stage kidney disease","volume":"13","author":"Bressendorff","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"2019060303554041000_gfz040-B41","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/ki.2011.44","article-title":"Warfarin-related nephropathy occurs in patients with and without chronic kidney disease and is associated with an increased mortality rate","volume":"80","author":"Brodsky","year":"2011","journal-title":"Kidney Int"},{"key":"2019060303554041000_gfz040-B42","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1001\/jamadermatol.2016.4821","article-title":"Warfarin-associated nonuremic calciphylaxis","volume":"153","author":"Yu","year":"2017","journal-title":"JAMA Dermatol"},{"key":"2019060303554041000_gfz040-B43","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1016\/j.jacc.2017.09.1087","article-title":"Renal outcomes in anticoagulated patients with atrial fibrillation","volume":"70","author":"Yao","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2019060303554041000_gfz040-B44","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur Heart J"},{"key":"2019060303554041000_gfz040-B45","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.kint.2017.06.005","article-title":"Warfarin in CKD patients with atrial fibrillation","volume":"92","author":"Brancaccio","year":"2017","journal-title":"Kidney Int"},{"key":"2019060303554041000_gfz040-B46","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1002\/jcph.628","article-title":"Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis","volume":"56","author":"Wang","year":"2016","journal-title":"J Clin Pharmacol"},{"key":"2019060303554041000_gfz040-B47","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1053\/j.ajkd.2015.01.022","article-title":"Dose-finding study of rivaroxaban in hemodialysis patients","volume":"66","author":"De Vriese","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"2019060303554041000_gfz040-B48","first-page":"287","article-title":"Oral anticoagulation in chronic kidney disease and atrial fibrillation","volume":"115","author":"Heine","year":"2018","journal-title":"Deutsches Arzteblatt Int"},{"key":"2019060303554041000_gfz040-B49","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1681\/ASN.2016090980","article-title":"Apixaban pharmacokinetics at steady state in hemodialysis patients","volume":"28","author":"Mavrakanas","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2019060303554041000_gfz040-B50","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/phar.1905","article-title":"Comparison of the safety and effectiveness of apixaban versus warfarin in patients with severe renal impairment","volume":"37","author":"Stanton","year":"2017","journal-title":"Pharmacotherapy"},{"key":"2019060303554041000_gfz040-B51","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1177\/1060028017694654","article-title":"Safety outcomes of apixaban compared with warfarin in patients with end-stage renal disease","volume":"51","author":"Sarratt","year":"2017","journal-title":"Ann Pharmacother"},{"key":"2019060303554041000_gfz040-B52","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1161\/CIRCULATIONAHA.118.035418","article-title":"Outcomes associated with apixaban use in patients with end-stage kidney disease and atrial fibrillation in the United States","volume":"138","author":"Siontis","year":"2018","journal-title":"Circulation"},{"key":"2019060303554041000_gfz040-B53","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ijcard.2018.11.119","article-title":"Cardiac valve calcification and use of anticoagulants: preliminary observation of a potentially modifiable risk factor","volume":"278","author":"Di Lullo","year":"2019","journal-title":"Int J Cardiol"},{"key":"2019060303554041000_gfz040-B54","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1161\/CIRCULATIONAHA.114.014113","article-title":"Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis","volume":"131","author":"Chan","year":"2015","journal-title":"Circulation"},{"key":"2019060303554041000_gfz040-B55","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1055\/s-0038-1669920","article-title":"Apixaban interacts with haemoglobin: effects on its plasma levels","volume":"118","author":"Sacco","year":"2018","journal-title":"Thromb Haemost"},{"key":"2019060303554041000_gfz040-B56","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1502000","article-title":"Idarucizumab for dabigatran reversal","volume":"373","author":"Pollack","year":"2015","journal-title":"N Engl J Med"},{"key":"2019060303554041000_gfz040-B57","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s40265-018-0940-4","article-title":"Andexanet alfa: first global approval","volume":"78","author":"Heo","year":"2018","journal-title":"Drugs"},{"key":"2019060303554041000_gfz040-B58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nefro.2017.11.004","article-title":"Spanish clinical guidelines on vascular access for haemodialysis","volume":"37","author":"Ibeas","year":"2017","journal-title":"Nefrologia"},{"key":"2019060303554041000_gfz040-B59","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","article-title":"2016 European guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)","volume":"37","author":"Piepoli","year":"2016","journal-title":"Eur Heart J"},{"key":"2019060303554041000_gfz040-B60","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.2337\/dc18-S009","article-title":"American Diabetes Association. Cardiovascular disease and risk management: standards of medical care in diabetes, 2018","volume":"41","year":"2018","journal-title":"Diabetes Care"},{"key":"2019060303554041000_gfz040-B61","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","article-title":"2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)","volume":"39","author":"Ibanez","year":"2018","journal-title":"Eur Heart J"},{"key":"2019060303554041000_gfz040-B62","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/eurheartj\/ehx095","article-title":"2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS): document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Endorsed by: the European Stroke Organization (ESO), the Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS)","volume":"39","author":"Aboyans","year":"2018","journal-title":"Eur Heart J"},{"key":"2019060303554041000_gfz040-B63","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.amjcard.2009.06.049","article-title":"A comparison of clopidogrel responsiveness in patients with versus without chronic renal failure","volume":"104","author":"Park","year":"2009","journal-title":"Am J Cardiol"},{"key":"2019060303554041000_gfz040-B64","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1053\/j.ajkd.2014.11.023","article-title":"Platelet reactivity after receiving clopidogrel compared with ticagrelor in patients with kidney failure treated with hemodialysis: a randomized crossover study","volume":"65","author":"Jeong","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"2019060303554041000_gfz040-B65"},{"key":"2019060303554041000_gfz040-B66"},{"key":"2019060303554041000_gfz040-B67","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1053\/j.ajkd.2012.08.031","article-title":"Antiplatelet therapy to prevent hemodialysis vascular access failure: systematic review and meta-analysis","volume":"61","author":"Palmer","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"2019060303554041000_gfz040-B68","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa1804988","article-title":"Effects of aspirin for primary prevention in persons with diabetes mellitus","volume":"379","author":"Bowman","year":"2018","journal-title":"N Engl J Med"},{"key":"2019060303554041000_gfz040-B69","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/S0140-6736(18)31924-X","article-title":"Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial","volume":"392","author":"Gaziano","year":"2018","journal-title":"Lancet"},{"key":"2019060303554041000_gfz040-B70","doi-asserted-by":"crossref","first-page":"445","DOI":"10.7326\/0003-4819-156-6-201203200-00007","article-title":"Effects of antiplatelet therapy on mortality and cardiovascular and bleeding outcomes in persons with chronic kidney disease: a systematic review and meta-analysis","volume":"156","author":"Palmer","year":"2012","journal-title":"Ann Intern Med"},{"key":"2019060303554041000_gfz040-B71","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1093\/ndt\/gft103","article-title":"Chronic kidney disease is associated with increased platelet activation and poor response to antiplatelet therapy","volume":"28","author":"Gremmel","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"2019060303554041000_gfz040-B72","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/sdi.12484","article-title":"Oral P2Y12 receptor inhibitors in hemodialysis patients undergoing percutaneous coronary interventions: current knowledge and future directions","volume":"29","author":"Jain","year":"2016","journal-title":"Semin Dial"},{"key":"2019060303554041000_gfz040-B73","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/ki.2013.170","article-title":"Major bleeding events and risk stratification of antithrombotic agents in hemodialysis: results from the DOPPS","volume":"84","author":"Sood","year":"2013","journal-title":"Kidney Int"},{"key":"2019060303554041000_gfz040-B74","first-page":"e10516","article-title":"The use of aspirin to reduce the risk of thrombotic events in patients with end-stage renal disease: protocol for a randomized controlled trial","volume":"7","author":"Lemos","year":"2018","journal-title":"J Med Internet Res"},{"key":"2019060303554041000_gfz040-B75","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ijcard.2017.03.026","article-title":"The pharmacodynamics of low and standard doses of ticagrelor in patients with end stage renal disease on hemodialysis","volume":"238","author":"Kim","year":"2017","journal-title":"Int J Cardiol"},{"key":"2019060303554041000_gfz040-B76","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/s00228-018-2484-7","article-title":"Pharmacokinetics and pharmacodynamics of ticagrelor in subjects on hemodialysis and subjects with normal renal function","volume":"74","author":"Teng","year":"2018","journal-title":"Eur J Clin Pharmacol"},{"key":"2019060303554041000_gfz040-B77","doi-asserted-by":"crossref","first-page":"262","DOI":"10.2215\/CJN.04430416","article-title":"Dual antiplatelet therapy and clinical outcomes after coronary drug-eluting stent implantation in patients on hemodialysis","volume":"12","author":"Chen","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"2019060303554041000_gfz040-B78","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/ijs.12254","article-title":"Effectiveness and safety of antiplatelet in stroke patients with end-stage renal disease undergoing dialysis","volume":"9","author":"Chen","year":"2014","journal-title":"Int J Stroke"},{"key":"2019060303554041000_gfz040-B79","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.carrev.2017.03.015","article-title":"Twelve-month outcome of patients with an established indication for oral anticoagulation undergoing coronary artery stenting and stratified by the baseline risk of bleeding: Insights from the Warfarin and Coronary Stenting (War-Stent) Registry","volume":"18","author":"Rubboli","year":"2017","journal-title":"Cardiovasc Revasc Med"},{"key":"2019060303554041000_gfz040-B80","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.amjcard.2016.06.018","article-title":"Evaluation of 5 prognostic scores for prediction of stroke, thromboembolic and coronary events, all-cause mortality, and major adverse cardiac events in patients with atrial fibrillation and coronary stenting","volume":"118","author":"Fauchier","year":"2016","journal-title":"Am J Cardiol"},{"key":"2019060303554041000_gfz040-B81","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/eurheartj\/ehy394","article-title":"2018 ESC\/EACTS Guidelines on myocardial revascularization","volume":"40","author":"Neumann","year":"2019","journal-title":"Eur Heart J"},{"key":"2019060303554041000_gfz040-B82","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.thromres.2005.03.028","article-title":"Low-molecular-weight heparins for the treatment of acute coronary syndrome and venous thromboembolism in patients with chronic renal insufficiency","volume":"118","author":"Lim","year":"2006","journal-title":"Thromb Res"},{"key":"2019060303554041000_gfz040-B83","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.jjcc.2017.10.018","article-title":"Efficacy and safety of bivalirudin in coronary artery disease patients with mild to moderate chronic kidney disease: meta-analysis","volume":"71","author":"Zeng","year":"2018","journal-title":"J Cardiol"},{"key":"2019060303554041000_gfz040-B84","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/jebm.12235","article-title":"Antithrombotic medications in dialysis patients: a double-edged sword","volume":"10","author":"Vlachopanos","year":"2017","journal-title":"J Evid-Based Med"},{"key":"2019060303554041000_gfz040-B85","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/ckj\/sfu080","article-title":"Anticoagulation in chronic kidney disease patients-the practical aspects","volume":"7","author":"Hughes","year":"2014","journal-title":"Clin Kidney J"},{"key":"2019060303554041000_gfz040-B86","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1007\/s11239-016-1363-2","article-title":"Erratum to: pharmacology of anticoagulants used in the treatment of venous thromboembolism","volume":"42","author":"Nutescu","year":"2016","journal-title":"J Thromb Thrombolysis"},{"key":"2019060303554041000_gfz040-B87","first-page":"373","article-title":"No accumulation of a prophylactic dose of nadroparin in moderate renal insufficiency","volume":"73","author":"Atiq","year":"2015","journal-title":"Neth J Med"},{"key":"2019060303554041000_gfz040-B88","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1001\/archinte.162.22.2605","article-title":"Is impaired renal function a contraindication to the use of low-molecular-weight heparin?","volume":"162","author":"Nagge","year":"2002","journal-title":"Arch Intern Med"},{"key":"2019060303554041000_gfz040-B89","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1093\/ckj\/sft083","article-title":"Preemptive dosage reduction of nadroparin in patients with renal failure: a retrospective case series","volume":"6","author":"Russcher","year":"2013","journal-title":"Clin Kidney J"},{"key":"2019060303554041000_gfz040-B90","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.thromres.2016.05.026","article-title":"Determining the safety of enoxaparin prophylaxis in critically ill patients with severe renal insufficiency\u2014The PACER pilot study","volume":"144","author":"Castellucci","year":"2016","journal-title":"Thrombosis Res"},{"key":"2019060303554041000_gfz040-B91","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1097\/MBC.0b013e328356717f","article-title":"Are low-molecular-weight heparins appropriately dosed in patients with CKD stage 3 to 5?","volume":"23","author":"Yildirim","year":"2012","journal-title":"Blood Coagul Fibrinolysis"},{"key":"2019060303554041000_gfz040-B92","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.amjmed.2012.09.021","article-title":"Low-molecular-weight or unfractionated heparin in venous thromboembolism: the influence of renal function","volume":"126","author":"Trujillo-Santos","year":"2013","journal-title":"Am J Med"},{"key":"2019060303554041000_gfz040-B93","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0002-8703(03)00121-2","article-title":"Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies","volume":"146","author":"Spinler","year":"2003","journal-title":"Am Heart J"},{"key":"2019060303554041000_gfz040-B94","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/ki.2013.152","article-title":"No difference in bleeding risk between subcutaneous enoxaparin and heparin for thromboprophylaxis in end-stage renal disease","volume":"84","author":"Chan","year":"2013","journal-title":"Kidney Int"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/34\/6\/923\/28750824\/gfz040.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,11]],"date-time":"2022-09-11T09:30:21Z","timestamp":1662888621000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/34\/6\/923\/5382166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,16]]},"references-count":94,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2019,3,16]]},"published-print":{"date-parts":[[2019,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfz040","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,6]]},"published":{"date-parts":[[2019,3,16]]}}}